<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195988</url>
  </required_header>
  <id_info>
    <org_study_id>IDS-CZD-piokal</org_study_id>
    <nct_id>NCT00195988</nct_id>
  </id_info>
  <brief_title>Comparison of Immunosuppression Protocols After LTx in Children</brief_title>
  <official_title>Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Memorial Health Institute, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Memorial Health Institute, Poland</source>
  <brief_summary>
    <textblock>
      Open label, randomised, prospective, onecentre Investigator Driven Study:&#xD;
&#xD;
      Comparison of two protocols of immunosuppression after liver Tx in children:&#xD;
&#xD;
      A: Study group - FK506-MMF. Immunosupression protocol: Methylprednisolone 10 mg/kg&#xD;
      intraoperatively i.v. FK506 Day 0 or 1 orally (0,15 mg/kg/D in two doses).MMF max. dosage 30&#xD;
      mg/kg/D p.o. day 0 through day 90.&#xD;
&#xD;
      B. Control group - Tacrolimus, steroids. Immunosupression protocol: Methylprednisolone 10&#xD;
      mg/kg bm intraoperatively Children &lt; 25kg bm: Methylprednisolone taper from 100 mg/D on day 0&#xD;
      to MP 10 mg on day 7 Children &gt; 25kg bm: Methylprednisolone taper from 200 mg/D on day 0 to&#xD;
      MP 20 mg on day 7 Week 2-4 Prednisone - 0,5-0,3 mg/kg/D; Week 4-12 Prednisone -0,3-0,2&#xD;
      mg/kg/D; Month 4-6 Prednisone 0,2 - 0,1 mg/kg/D Month 7 - Steroid withdrawal FK506 Day 0 or 1&#xD;
      orally (0,15 mg/kg/D in two doses).&#xD;
&#xD;
      Primary end points:&#xD;
&#xD;
      Number of rejections, number of steroid-resistant rejections.&#xD;
&#xD;
      Secondary end points:&#xD;
&#xD;
      Patients and graft survival Dyslipidemia one year after transplantation Hypertension one year&#xD;
      after transplantation Hyperglycemia/Diabetes de novo one year after transplantation Renal&#xD;
      function before Tx and 1 year after Tx&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A: Study group&#xD;
&#xD;
      FK506-MMF.&#xD;
&#xD;
      Immunosupression protocol:&#xD;
&#xD;
      Metylprednisolon 10 mg/kg intraoperatively i.v.&#xD;
&#xD;
      FK506 Day 0 or 1 oraly (0,15 mg/kg/D in two doses).&#xD;
&#xD;
      MMF max. dosage 30 mg/kg/D p.o. day 0 through day 90 according to patient condition and&#xD;
      therapeutic MMF blood concentration&#xD;
&#xD;
      Tailoring:&#xD;
&#xD;
      Immunosupression protocol will be tailored according to the cause of liver failure: patients&#xD;
      with autoimmune liver disease (autoimmune hepatitis, PBC, PSC, overlap syndrome etc) would be&#xD;
      maintained on MMF. All other recipients including cryptogenic liver cirrhosis will be&#xD;
      gradually (over 1 month) withdrawn from MMF administration 90 days after transplantation if&#xD;
      there is:&#xD;
&#xD;
        1. good kidney function (S-creatinin &lt; 150 umol/l) enabling to achieve and maintain&#xD;
           Tacrolimus trough levels above 6 ng/ml and&#xD;
&#xD;
        2. if there was no more than one episode of acute rejection of the graft which resolved&#xD;
           completely.&#xD;
&#xD;
      Targeted Tacrolimus trough levels:&#xD;
&#xD;
      Month 1 - 3 through levels 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 10 - 6 ng/ml&#xD;
&#xD;
      Rejection treatment:&#xD;
&#xD;
        1. Tacrolimus dose adjustment to upper limit of target level if last Tacrolimus trough&#xD;
           level is below the intended limit.&#xD;
&#xD;
        2. Steroid boluses would be administered Metylprednisolon 10 mg/kg daily 3 consecutive&#xD;
           days. No steroid taper. Control biopsy after normalisation of LFTs.&#xD;
&#xD;
        3. After two attacks of acute rejection before MMF disontinuation Prednison dose would be&#xD;
           introduced on at least 0,3 mg/D for 3 months.&#xD;
&#xD;
        4. After second attack of AR after MMF discontinuation Prednison dose would be introduced&#xD;
           on at least 0,3 mg/D for 6 months.&#xD;
&#xD;
        5. Steroid resistant rejection: biopsy proven rejection persisting after three courses of&#xD;
           steroid pulses. Steroid resistant rejection would be treated according to local praxis.&#xD;
&#xD;
      Concomitant drugs:&#xD;
&#xD;
      Antiviral and antibacterial prophylaxis according to current centre praxis. Prophylaxis of&#xD;
      cholestasis and prophylaxis/treatment of the bone disease where applicable.&#xD;
&#xD;
      B. Control group&#xD;
&#xD;
      Tacrolimus, steroids.&#xD;
&#xD;
      Immunosupression protocol:&#xD;
&#xD;
      Metylprednisolon 10 mg/kg bm intraoperatively Children &lt; 25kg bm: Metylprednisolon taper from&#xD;
      100 mg/D on day 0 to MP 10 mg on day 7 Children &gt; 25kg bm: Metylprednisolon taper from 200&#xD;
      mg/D on day 0 to MP 20 mg on day 7 Week 2-4 Prednison - 0,5-0,3 mg/kg/D Week 4-12 Prednison&#xD;
      -0,3-0,2 mg/kg/D Month 4-6 Prednison 0,2 - 0,1 mg/kg/D Month 7 - Steroid withdrawal&#xD;
&#xD;
      FK506 Day 0 or 1 orally (0,15 mg/kg/D in two doses).&#xD;
&#xD;
      Intended Tacrolimus trough levels:&#xD;
&#xD;
      Month 1 -3 through levels 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 6-10 ng/ml&#xD;
&#xD;
      Rejection treatment:&#xD;
&#xD;
        1. Tacrolimus dose adjustment to upper limit of target level if last Tacrolimus trough&#xD;
           level is below the intended limit.&#xD;
&#xD;
        2. Steroid boluses would be administered Metylprednisolon 10 mg/kg bm daily 3 consecutive&#xD;
           days. No steroid taper, return to previous steroid dose. Control biopsy after&#xD;
           normalisation of LFTs.&#xD;
&#xD;
        3. After two attacks of acute rejection Prednison dose would be maintained on at least 0,3&#xD;
           mg/D for 3 months.&#xD;
&#xD;
        4. Steroid resistant rejection: biopsy proven rejection persisting after three courses of&#xD;
           steroid pulses. Steroid resistant rejection would be treated according to local praxis.&#xD;
&#xD;
      Biopsy: Liver biopsy should be taken in any suspicion of graft rejection or disease&#xD;
      recurrence. Protocol biopsy would be taken according to local practice, liver biopsy in&#xD;
      one-year after transplantation is mandatory.&#xD;
&#xD;
      Primary end points:&#xD;
&#xD;
      Number of rejections, number of steroid-resistant rejections.&#xD;
&#xD;
      Secondary end points:&#xD;
&#xD;
      Patients and graft survival Dyslipidemia one year after transplantation Hypertension one year&#xD;
      after transplantation Hyperglycemia/Diabetes de novo one year after transplantation Renal&#xD;
      function before Tx and 1 year after Tx&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Subjects who meet all of the following criteria are eligible for this study:&#xD;
&#xD;
        1. Male or female patients, not older than 18 years old.&#xD;
&#xD;
        2. Primary liver transplantation&#xD;
&#xD;
        3. Patient is capable of understanding the purpose and risks of the study and has been&#xD;
           informed both orally and in writing and has given informed consent&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      Subjects who meet one or more of the following criteria are not eligible for this study:&#xD;
&#xD;
        1. Female patients who are pregnant or are breast feeding&#xD;
&#xD;
        2. Patients &gt; 18 years old&#xD;
&#xD;
        3. Combined liver-kidney transplantation&#xD;
&#xD;
        4. Recipient of second liver graft&#xD;
&#xD;
        5. Patients are allergic, hyper-sensitive or intolerant to HCO-60 or structurally related&#xD;
           compounds, macrolide antibiotics or tacrolimus.&#xD;
&#xD;
        6. Patients with known HIV-anamnesis&#xD;
&#xD;
        7. Patient requires ongoing dosing with a systemic immunosuppressive drug at study entry&#xD;
           for another indication than the prophylaxis of liver graft rejection&#xD;
&#xD;
        8. Patient has significant, uncontrolled concomitant infections and/or severe diarrhea,&#xD;
           vomiting, or active peptic ulcer.&#xD;
&#xD;
        9. Patient is participating or has participated in another clinical study and/or is taking&#xD;
           or has been taking an investigational drug in the past 28 days.&#xD;
&#xD;
       10. Other reasons which depend on the assessment of the physician (no MMF will be given to&#xD;
           patients with severe persistent hypersplenism (WBC &lt; 3.500/ml, platelets &lt; 50.000/ml)&#xD;
&#xD;
      Informed Consent:&#xD;
&#xD;
      Patient, who will give written consent for participation in the study and will fulfil all the&#xD;
      inclusion and exclusion criteria, will be included in the study. After inclusion into the&#xD;
      study, the patient may withdraw at any time for any reason.&#xD;
&#xD;
      Follow-up: (time of one patient observation ) -12 months&#xD;
&#xD;
      Number of centers: 1 Number of patients: 40 Indication: - Primary Liver transplantation&#xD;
      Duration of study: 36 months Enrollment period: 18 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of rejections, number of steroid-resistant rejections.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients and graft survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyslipidemia one year after transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension one year after transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia/Diabetes de novo one year after transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function before Tx and 1 year after Tx</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus, steroids, mycophenolate mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet all of the following criteria are eligible for this study:&#xD;
&#xD;
               1. Male or female patients, not older than 18 years old.&#xD;
&#xD;
               2. Primary liver transplantation&#xD;
&#xD;
               3. Patient is capable of understanding the purpose and risks of the study and has&#xD;
                  been informed both orally and in writing and has given informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet one or more of the following criteria are not eligible for this&#xD;
             study:&#xD;
&#xD;
               1. Female patients who are pregnant or are breast feeding&#xD;
&#xD;
               2. Patients &gt; 18 years old&#xD;
&#xD;
               3. Combined liver-kidney transplantation&#xD;
&#xD;
               4. Recipient of second liver graft&#xD;
&#xD;
               5. Patients are allergic, hyper-sensitive or intolerant to HCO-60 or structurally&#xD;
                  related compounds, macrolide antibiotics or tacrolimus.&#xD;
&#xD;
               6. Patients with known HIV-anamnesis&#xD;
&#xD;
               7. Patient requires ongoing dosing with a systemic immunosuppressive drug at study&#xD;
                  entry for another indication than the prophylaxis of liver graft rejection&#xD;
&#xD;
               8. Patient has significant, uncontrolled concomitant infections and/or severe&#xD;
                  diarrhoea, vomiting, or active peptic ulcer.&#xD;
&#xD;
               9. Patient is participating or has participated in another clinical study and/or is&#xD;
                  taking or has been taking an investigational drug in the past 28 days.&#xD;
&#xD;
              10. Other reasons which depend on the assessment of the physician (no MMF will be&#xD;
                  given to patients with severe persistent hypersplenism (WBC &lt; 3.500/ml, platelets&#xD;
                  &lt; 50.000/ml)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kalicinski, Prof., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Memorial Health Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatric Surgery and Organ Transplantation, CMHI</name>
      <address>
        <city>Warsaw</city>
        <zip>04-743</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 16, 2005</last_update_submitted>
  <last_update_submitted_qc>November 16, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2005</last_update_posted>
  <keyword>immunosuppression,</keyword>
  <keyword>steroid avoidance,</keyword>
  <keyword>liver transplantation,</keyword>
  <keyword>children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

